Corey Ritter
ARCH Venture Partners
Greater Chicago Area
Overview
Work Experience
Principal
2017 - Current
ARCH creates and invests in companies commercializing disruptive new technology developed by leading scientific researchers. I focus on life science tools and therapeutic platforms. Also: biotechnology, diagnostics, medical devices, quantum computing, materials, semiconductors, nanotechnology, autonomous systems, additive manufacturing, robotics.
ARCH is a venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Board Member
2021
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Raised $49,227,275.00 from Northpond Ventures, Anterra Capital, ARCH Venture Partners, Northpond Ventures, ARCH Venture Partners and Anterra Capital.
Board Member
2021
Quantum Circuits is developing and commercializing quantum computing technology that utilizes superconducting quantum circuits.
Raised $78,000,000.00 from F-Prime Capital, Tribeca Venture Partners, Fitz Gate Ventures, Hither Creek Ventures, Canaan Partners, Sequoia Capital, ARCH Venture Partners, IQT, Connecticut Innovations and OUP (Osage University Partners).
Board Observer
2019
Business development for company creation; led Series A financing.
Vizgen is a biotech company that develops solutions for next-generation spatially resolved, single-cell transcriptomics.
Raised $136,200,000.00 from ARCH Venture Partners, Northpond Ventures and Tao Capital Partners.
Board Observer
2019
Business development for company creation; led Series A financing.
Scale Biosciences is a single-cell profiling and analysis solutions company for genomic, transcriptomic, and multi-omic applications.
Board Observer
2022
Elephas harnesses latest advances in cancer biology, multimodal microscopy, and artificial intelligence to empower clinical decision-making.
Raised $123,500,000.00 from Venture Investors, TAO Investments, State of Wisconsin Investment Board, WARF Ventures, Sands Capital Ventures, ARCH Venture Partners, Northpond Ventures and Moore Strategic Ventures.
Board Observer
2018 - 2021
NASDAQ: MASS
908devices manufactures battery-operated, hand-held chemical detection tools used in mass spectrometry.
Raised $167,800,000.00 from Northpond Ventures, Saudi Aramco Energy Ventures, Razor's Edge Ventures, Tao Capital Partners, Casdin Capital, SLB, Sands Capital Ventures and ArchVentures SA.
George Schultz Innovation Fund Associate
2017 - 2017
The Innovation Fund invests in science-based startups emanating from U-Chicago and Argonne National Lab. I led seed investments in two pre-clinical therapeutics startups.
Business Development
2017 - 2017
Startup commercializing novel water de-ionization materials technology developed at Argonne National Lab for use in water cooling towers. We competed in Chicago-Booth's New Venture Challenge
Associate
2016 - 2017
Led screening and diligence for healthcare tech investments.
Hands-on, collaborative, and entrepreneur friendly early stage VC.